Quantcast

Latest Medicinal chemistry Stories

2014-02-20 23:27:10

Today, it's vitally necessary that drug and device manufacturers have a proactive recall strategy that will work effectively in the United States and every country where your products are sold. Drug and Device Recalls Bootcamp will provide manufacturers with what they must know now about recall readiness — real-life lessons, invaluable tips and proven techniques to take back and deploy at once. Falls Church, VA (PRWEB) February 20, 2014 Drug and Device Recalls Bootcamp **Presented...

2014-02-17 23:22:46

FDAnews’ editors monitor and report on regulatory developments affecting device production in more than 45 nations around the world. They’ve compiled more than 150 reports highlighting changes from the past year that will keep devicemakers growing in international markets. Falls Church, VA (PRWEB) February 17, 2014 Guide to International Medical Device Regulation — 2014 Edition **FDAnews Publication** http://www.fdanews.com/IMDRM14 In medical device manufacturing, success means...

2014-02-15 23:01:13

RnRMarketResearch.com adds “High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services – Global Forecasts to 2018” to its store. Dallas, Texas (PRWEB) February 15, 2014 The global high content screening market is a technology-driven market and is marked by the ‘Threat of Obsolescence,’ wherein technologies as...

2014-02-13 12:27:40

MILLBROOK, N.Y., Feb. 13, 2014 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Adam J. Stein, Ph.D. to its Scientific Advisory Committee. Dr. Stein has over eighteen years of experience in structural biology, with the last seven in applying structural biology and biophysical chemistry to the drug discovery efforts in biotech. While at deCODE Genetics, he was able to design fragment libraries that enabled us to elucidate...

2014-02-12 23:00:49

The Firm is evaluating GranuFlo lawsuits on behalf of individuals who allegedly suffered heart attacks, strokes, and other life-threatening heart events within 72 hours of a dialysis treatment with GranuFlo or NaturaLyte dialysis drugs. New York, New York (PRWEB) February 12, 2014 Dialysis patients who allegedly suffered life-threatening heart events following administration of GranuFlo or NaturaLyte dialysis drugs continue to file GranuFlo lawsuits (http://www.thegranuflolawsuit.com/)...

2014-02-12 16:27:03

Company will Host Conference Call on February 13, 2014 CUPERTINO, Calif., Feb. 12, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for POSIDUR((TM)) (SABER(®)-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia. Based on its review, the FDA has determined that they cannot approve the NDA in its present form,...

2014-02-12 08:28:31

LITTLE ROCK, AR, Feb. 12, 2014 /CNW/ - (TSX-V:VBI) - Vivione Biosciences Inc. ("Vivione") is pleased to announce the signing of a Memorandum of Understanding ("MOU") with South Korean biotech company, AriBio, Inc. ("AriBio"). This strategic alliance is anticipated to combine the strengths of Vivione in the areas of rapid diagnostics and its new in silico compound modeling technology ("Molecular Design") with AriBio's substantial experience in drug design and testing. The alliance...

2014-02-11 20:21:26

DUBLIN, February 11, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/tgtpbg/drug_solubility) has announced the addition of the "Concise Analysis of Drug Solubility Technology: Spray Drying, Extrusion, and SCF" [http://www.researchandmarkets.com/research/tgtpbg/drug_solubility ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) As drug suppliers re-examine their business models to adjust...

2014-02-11 08:33:50

NEW YORK, Feb. 11, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of The Medicines Company ("Medicines" or the "Company") (NasdaqGS: MDCO). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. The investigation concerns whether Medicines and certain of its officers and/or directors...

2014-02-11 08:32:03

Company adds Scott Biller to its Scientific Advisory Board NEW HAVEN, Conn., Feb. 11, 2014 /PRNewswire/ -- Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced the appointment of Jim Winkler, Ph.D., to the position of Chief Scientific Officer. Dr. Winkler will be responsible for the discovery and development of potential drug compounds that will target specific disease-driving proteins for degradation. In addition, the...


Latest Medicinal chemistry Reference Libraries

European Journal of Medical Chemistry
2012-05-12 22:03:06

The European Journal of Medical Chemistry is a peer-reviewed scientific journal for medical chemistry. It is published by Elsevier. It was established in 1966 under the title Chimica Therapeutica. That name was maintained until 1973. Even after changing to its current name in 1974, the journal was still subtitled Chimica Therapeutica until 1981; from 1982 to 1986 it was subtitled Chimie Therapeutique, indicating its French origin. The Journal publishes studies on all aspects of medicinal...

More Articles (1 articles) »
Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related